Focused On-demand Library for Decapping and exoribonuclease protein

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.







Alternative names:

5'-3' exoribonuclease DXO; Dom-3 homolog Z; NAD-capped RNA hydrolase DXO

Alternative UPACC:

O77932; A2CER3; B0UZ80; O15004; O78127; O78128; Q5ST60; Q6IPZ2; Q9NPK4


The Decapping and exoribonuclease protein, also known as 5'-3' exoribonuclease DXO, Dom-3 homolog Z, and NAD-capped RNA hydrolase DXO, plays a crucial role in RNA metabolism. It uniquely hydrolyzes the NAD cap from specific RNAs, promoting their decay, and acts on NAD-capped transcripts under environmental stress. Unlike canonical decapping enzymes, it removes the entire cap structure of m7G capped or incompletely capped RNAs, ensuring the degradation of defective pre-mRNAs. Additionally, it exhibits 5'-3' exoribonuclease and RNA 5'-pyrophosphohydrolase activities, further contributing to RNA processing and turnover.

Therapeutic significance:

Understanding the role of Decapping and exoribonuclease protein could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.